Completed
Treatment of Panic Disorder Long Term Strategies
Led by New York State Psychiatric Institute · Updated on 2014-03-18
379
Participants Needed
4
Research Sites
N/A
Total Duration
On this page
Sponsors
N
New York State Psychiatric Institute
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cognitive behavior therapy (CBT) with or without medication has been used in the treatment of panic disorder (PD). The purpose of this study is 1) to determine whether nine months of maintenance cognitive-behavior therapy (CBT) significantly improves the likelihood of sustained improvement; and 2) to determine the acute acceptability and efficacy of medication therapy or continued CBT alone among patients who fail to respond sufficiently to an initial course of CBT alone. It has been found that patients with PD respond as well to CBT or medication alone as they do to a combination of the two. Since the combined treatments are expensive and CBT is associated with less risk of medical toxicity compared to medications, CBT alone will be used first. All patients will first receive CBT alone. If the patient responds to this therapy, the patient will be assigned randomly (like tossing a coin) to 1 of 2 groups. One group will continue to receive CBT (maintenance therapy) for 9 months. The other group of responders will not receive any further therapy. If a patient does not respond to CBT alone, he/she will be assigned randomly to 1 of 2 different groups. One group will receive paroxetine; the other will continue to receive CBT for a longer period. The response to treatment will be evaluated to see which regimen works best to treat PD. The study will last approximately 3 years. An individual may be eligible for this study if he/she has panic disorder with no more than mild agoraphobia (fear of being in public places) and is at least 18 years old.
CONDITIONS
Brief Title
Treatment of Panic Disorder: Long Term Strategies
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- primary diagnosis of Panic disorder with or without Agoraphobia (all levels of agoraphobia are included).
Exclusion Criteria:
- current substance abuse or dependence,
- current active suicidal potential;
- any history of psychosis, bipolar disorder (I or II) or cyclothymia;
- pending application or existing medical disability claim;
- significant cognitive impairment,
- current uncontrolled general medical illness requiring intervention,
- psychotherapy directed at anxiety or panic which will not be discontinued by the first treatment visit, and daily use of 2mg of Xanax or equivalent.
Exclusion criteria for paroxetine study:
- hypersensitivity to Selective Serotonin Reuptake Inhibitors (SSRI),
- pregnancy, lactation, or planned pregnancy during the course of the study,
- contemporaneous medication that may interfere or interact with paroxetine,
- prior treatment with therapeutic doses of paroxetine (40mg/d for 1 mo),
- concurrent treatment with antidepressants.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here